Trial results: AXIRON may be good for testosterone deficiency

Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of Axiron in 155 men with testosterone deficiency (hypogonadism).

Axiron is applied to the underarm using a unique “no-touch” applicator. Subjects were permitted to use an underarm deodorant or antiperspirant during the trial. More than half of the men continued to apply an underarm deodorant or antiperspirant as part of their daily routine, and an analysis of these subgroups showed that this had no impact on the efficacy of Axiron treatment.

After only two weeks of treatment, it was found that 76 percent of subjects had average blood levels of testosterone within the normal range. Analysis of mood, sexual desire, sexual activity and sexual performance before and after four months of treatment showed significant improvement from baseline across all measures.